The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.
 
Paul K. Paik
Honoraria - Bicara Therapeutics; Crown Bioscience; EMD Serono; Janssen Oncology; Mirati Therapeutics; Takeda
Consulting or Advisory Role - Bicara Therapeutics; Crown Bioscience; EMD Serono; Janssen Oncology; Mirati Therapeutics; Takeda
Research Funding - Bicara Therapeutics; Boehringer Ingelheim; EMD Serono
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; MSD Oncology; Novartis; Pfizer; Regeneron; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ArriVent Biopharma; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Novartis; Sensei Biotherapeutics; Spectrum Pharmaceuticals
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Spectrum Pharmaceuticals
 
Michael Thomas
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; Janssen Oncology; Lilly O.; Merck KGaA; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb; Merck KGaA; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Pharmaceutical; Janssen Oncology; Lilly O.; Merck KGaA; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
 
Hiroshi Sakai
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
 
Remi Veillon
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Roche; Sanofi/Aventis; Takeda
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer
 
Egbert F. Smit
Honoraria - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Merck KGaA; Merck KGaA
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Julien Mazieres
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Pharmaceutical; Merck KGaA; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Alexis B Cortot
Honoraria - Amgen; AstraZeneca; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Janssen; Novartis; Pfizer; Takeda
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche
 
Jo Raskin
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly O.; Merck KGaA; Pfizer
 
Santiago Viteri
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; Merck KGaA; MSD; OSE Pharma; Puma Biotechnology; Roche
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Jun Zhao
No Relationships to Disclose
 
Svenja Adrian
Employment - Merck KGaA
 
Karin Berghoff
Employment - Merck KGaA
 
Rolf Bruns
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Andreas Johne
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS